Strides Pharma Science Ltd

Net profit of Strides Pharma Science rose 54.45% to Rs 126.94 crore in the quarter ended March 2026 as against Rs 82.19 crore during the previous quarter ended March 2025. Sales rose 11.18% to Rs 1323.47 crore in the quarter ended March 2026 as against Rs 1190.39 crore during the previous quarter ended March 2025. For the full year,net profit declined 84.52% to Rs 556.19 crore in the year ended March 2026 as against Rs 3593.46 crore during the previous year ended March 2025. Sales rose 6.43% to Rs 4858.68 crore in the year ended March 2026 as against Rs 4565.34 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1323.471190.39 11 4858.684565.34 6 OPM %18.1118.30 -19.0417.58 - PBDT207.71182.66 14 897.93614.52 46 PBT154.46133.80 15 695.53422.26 65 NP126.9482.19 54 556.193593.46 -85 Powered by Capital Market - Live

Revenue from operations rose 11.17% YoY to Rs 1,323.47 crore in the quarter ended 31 March 2026. Profit before exceptional items and tax increased 17.09% YoY to Rs 153.01 crore, while the company also reported an exceptional loss of Rs 6.41 crore during the quarter. EBITDA stood at Rs 239.7 crore in Q4 FY26, registering a growth of 10% compared with Rs 217.9 crore in Q4 FY25. EBITDA margin declined by 20 basis points to 18.1% in Q4 FY26, as against 18.3% in Q4 FY25. For the full financial year FY26, the company reported an 84.52% tumble in net profit to Rs 556.19 crore, compared with Rs 556.19 crore in the previous year. Revenue from operations rose 6.42% to Rs 4,858.68 crore in FY26. For the full year, the company's US market revenue stood at Rs 2,489.7 crore, growing 2% year-on-year, while Ex-US market revenue rose sharply by 21% to Rs 2,240.4 crore, emerging as the key growth driver for the business. The company reported net debt of Rs 1,436.5 crore, impacted by forex depreciation of Rs 111.5 crore. Net debt-to-EBITDA improved to 1.55x in FY26 from 1.9x in FY25, while RoCE rose to 15.8% from 14.9%. Badree Komandur, MD & Group CEO, said, 'Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex‑US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex‑US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth.' Meanwhile, the company's board has recommended a final dividend of Rs 5 per equity share of face value Rs 10 each, representing 50% of the face value, for the financial year ended 31 March 2026. The record date for determining shareholders eligible for the dividend will be fixed and intimated in due course. The dividend, subject to shareholders' approval at the ensuing Annual General Meeting (AGM), will be paid within 30 days from the date of approval after deduction of applicable tax at source. Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products. Powered by Capital Market - Live

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 18 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 18 May 2026.

In a regulatory filing made after market hours yesterday, the company informed that its step- down subsidiary, Strides Pharma International AG (SPIAG) has entered into definitive agreements with Sandoz AG, Switzerland, for the acquisition and in-licensing of a portfolio of branded generic products across Sub Saharan Africa (SSA). The agreement spans four key markets, which include Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti-infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding $1 million, reflecting their established brand equity and market demand. The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. To ensure the uninterrupted availability of these critical brands, Strides will also enter into a manufacturing and supply agreement with Sandoz for their continued production and supply. With the combined strength of Strides' existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the representable market. Strides Pharma further said that the initial consideration for the transaction is $12 million, payable at closing and is expected to be funded through internal accruals. The arrangement also provides for yearly royalty payments to the Sandoz based on a percentage of net sales for the distribution products. The transaction is expected to be EPS accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage. The transaction is expected to close by the end of Q2 FY27 (quarter ending 30 September 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions. Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company focused on regulated and emerging markets, with manufacturing facilities across India, Italy, Kenya and the US, and a presence in over 100 countries. On a consolidated basis, the company's profit after tax rose 131.14% YoY to Rs 208.12 crore in Q3 FY26 from Rs 90.04 crore a year ago. Revenue increased 3.6% YoY to Rs 1,194.6 crore in Q3 FY26. Powered by Capital Market - Live

Strides Pharma Science announced that Strides Pharma Inc. (SPI), a step-down wholly owned subsidiary of the Company in the USA, has received the USFDA Inspection Closure Report (Establishment Inspection Report - EIR) for its Formulations Facility located at Chestnut Ridge, New York, USA. The Facility was inspected by the United States Food and Drug Administration (USFDA) from 17 December 2025 to 23 December 2025. The inspection covered current Good Manufacturing Practices (cGMP) and included a pre-approval inspection for Drug-Device Combination capabilities, covering the Company's recent filing in Nasal Sprays domain. Based on SPI's response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (Voluntary Ac on Indicated). The EIR states that the inspection has been closed. The Chestnut Ridge facility caters to the U.S. market and manufactures Liquids, Gels, Hormones, Modified Release products and Controlled Substances, supporting several current and future products for the U.S. market. The successful closure of this inspection including Device Combinations further strengthens the Company's U.S. business and near term growth prospects.Powered by Capital Market - Live

On a consolidated basis, profit after tax rose 131.14% YoY to Rs 208.12 crore in Q3 FY26 from Rs 90.04 crore a year ago. On a sequential basis, PAT rose 58.24% QoQ from Rs 131.52 crore. Operational profit after tax rose 38.6% YoY to Rs 128.2 crore in Q3 FY26 from Rs 92.5 crore a year ago. On a sequential basis, operational PAT declined 8.6% QoQ from Rs 140.3 crore. Revenue increased 3.6% YoY to Rs 1,194.6 crore in Q3 FY26 compared with Rs 1,153.7 crore in Q3 FY25. Sequentially, revenue declined 2.1% QoQ from Rs 1,220.8 crore. Revenue was impacted by low offtake in the institutional business and flattish US operations. Gross profit rose 8.6% YoY to Rs 731.7 crore from Rs 673.5 crore. Gross margin expanded sharply to 61.2%, an improvement of 280 bps YoY and 340 bps QoQ. EBITDA increased 12.2% YoY to Rs 235.9 crore in Q3 FY26 from Rs 210.3 crore, while rising 1.9% QoQ. EBITDA margin improved to 19.8%, up 160 bps YoY and 80 bps sequentially. Ex-US market revenue stood at $64 million, registering a strong 20% YoY growth. Growth was led by other regulated markets and growth markets, which helped offset weak institutional demand and flat US performance. Management reiterated continued investments in sustainable long-term growth and announced the appointment of Peter Hardwick as CEO of the North America business. Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company focused on regulated and emerging markets, with manufacturing facilities across India, Italy, Kenya and the US, and a presence in over 100 countries. Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 129.80% to Rs 202.11 crore in the quarter ended December 2025 as against Rs 87.95 crore during the previous quarter ended December 2024. Sales rose 3.55% to Rs 1194.65 crore in the quarter ended December 2025 as against Rs 1153.67 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1194.651153.67 4 OPM %19.7518.23 - PBDT299.40164.70 82 PBT248.78116.28 114 NP202.1187.95 130 Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live

In an exchange filing, the company said the current Good Manufacturing Practices (cGMP) inspection was conducted by the US Food and Drug Administration (USFDA) at the facility between 17 December and 23 December 2025. At the conclusion of the inspection, the regulator issued a Form 483 containing four observations. The company clarified that the observations are procedural in nature and are not expected to have any impact on the supply of its commercial products. SPI will submit a comprehensive response to the USFDA within the stipulated timeframe and expressed confidence in addressing all the observations to the regulator's satisfaction. Strides Pharma further stated that it will keep the stock exchanges informed of any further developments in this matter. The official announcement was made on 24 December 2025, after market hours. Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products. The company's consolidated net profit jumped 81.98% to Rs 131.52 crore on a 4.62% increase in revenue from operations to Rs 1,220.83 crore in Q2 Sept 2025 over Q2 Sept 2024. Powered by Capital Market - Live